{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-030746","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.132888+00:00","generated_at":"2026-05-31T11:03:00.296744+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Co-Diagnostics Q2 revenue jumps to $2.7M, net loss narrows to $7.6M, submits 510(k) for PCR platform","bullets":["Revenue of $2.7M vs $0.2M in prior year, driven by milestone achievements on grants.","Net loss of $7.6M ($0.25/share) improved from $8.9M ($0.31/share) YoY; adjusted EBITDA loss of $5.9M.","Operating loss of $7.7M compared to $12.0M in 2023; cash and securities of $44.9M as of June 30.","Submitted first 510(k) for Co-Dx PCR Pro platform with OTC COVID-19 test to FDA.","Opened new manufacturing facility in South Salt Lake for Co-Primers and PCR platform components."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-030746","json":"https://secwatch.observer/filing/0001493152-24-030746.json","markdown":"https://secwatch.observer/filing/0001493152-24-030746.md","text":"https://secwatch.observer/filing/0001493152-24-030746.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315224030746/0001493152-24-030746-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315224030746/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:03:00.296744+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}